A Human Stem Cell Model of Fabry Disease Implicates LIMP-2 Accumulation in Cardiomyocyte Pathology

Abstract

Summary: Here, we have used patient-derived induced pluripotent stem cell (iPSC) and gene-editing technology to study the cardiac-related molecular and functional consequences of mutations in GLA causing the lysosomal storage disorder Fabry disease (FD), for which heart dysfunction is a major cause of mortality. Our in vitro model recapitulated clinical data with FD cardiomyocytes accumulating GL-3 and displaying an increased excitability, with altered electrophysiology and calcium handling. Quantitative proteomics enabled the identification of >5,500 proteins in the cardiomyocyte proteome and secretome, and revealed accumulation of the lysosomal protein LIMP-2 and secretion of cathepsin F and HSPA2/HSP70-2 in FD. Genetic correction reversed these changes. Overexpression of LIMP-2 directly induced the secretion of cathepsin F and HSPA2/HSP70-2, implying causative relationship, and led to massive vacuole accumulation. In summary, our study has revealed potential new cardiac biomarkers for FD, and provides valuable mechanistic insight into the earliest pathological events in FD cardiomyocytes. : In this article, using an iPSC model, gene editing, and quantitative proteomics, Birket and colleagues gain unique insight into the molecular and functional consequences of heart disease-associated GLA mutations in human cardiomyocytes. They identified a panel of cell and secreted biomarkers, the discovery of which may have significant therapeutic relevance for Fabry disease and other lysosomal storage disorders. Key words: Fabry disease, iPSC, cardiomyocyte, heart, lysosome, proteomics, secretome, biomarkers, LIMP-2, maturation